JW HOLDINGS CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,980 KRW | -1.00% |
|
+0.68% | -14.61% |
| 03-20 | JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023 | MT |
| 03-18 | JW Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 865B 629M 858M | Sales 2023 | 928B 675M 922M | Capitalization | 252B 183M 250M |
|---|---|---|---|---|---|
| Net income 2022 | 22.15B 16.1M 22M | Net income 2023 | 19.03B 13.83M 18.89M | EV / Sales 2022 | 0.69 x |
| Net Debt 2022 | 389B 283M 386M | Net Debt 2023 | 400B 291M 397M | EV / Sales 2023 | 0.7 x |
| P/E ratio 2022 |
9.25
x | P/E ratio 2023 |
13.2
x | Employees | 141 |
| Yield 2022 |
3.36% | Yield 2023 |
2.95% | Free-Float | 46% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -1.00% | ||
| 1 week | +0.68% | ||
| Current month | -4.64% | ||
| 1 month | -6.88% | ||
| 3 months | -8.45% | ||
| 6 months | -4.42% | ||
| Current year | -14.61% |
1 week
2 900.00
3 075.00
1 month
2 880.003 200.00
Current year
2 880.003 485.00
1 year
2 880.004 397.06
3 years
2 536.654 574.36
5 years
2 536.656 924.97
10 years
1 692.4616 326.20
| Managers | Title | Age | Since |
|---|---|---|---|
Sung-Kweon Han
CEO | Chief Executive Officer | 66 | - |
Kyung-Ha Lee
CEO | Chief Executive Officer | 60 | - |
Ji-Woo Choi
DFI | Director of Finance/CFO | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kyung-Ha Lee
CEO | Chief Executive Officer | 60 | - |
Jong-Ho Lee
BRD | Director/Board Member | 91 | - |
Sung-Kweon Han
CEO | Chief Executive Officer | 66 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2,980 | -1.00% | 545,645 |
| 24-04-25 | 3,010 | -0.17% | 24,883 |
| 24-04-24 | 3,015 | +0.84% | 32,335 |
| 24-04-23 | 2,990 | +0.50% | 18,493 |
| 24-04-22 | 2,975 | +0.51% | 20,601 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
JW Holdings Corp is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company operates its business through four segments. The Pharmaceutical segment is involved in the manufacturing and sale of pharmaceuticals. Its major products include antibiotics, antifungal agents, blood and body fluids substitutes, hyperlipidemia drugs, electrolyte additives, angina pills, and digestive medicines. The Medical Equipment segment manufactures and sells medical equipment such as diagnostic equipment, diagnostic reagents, surgical operating tables, and surgical mooyoung lamp. The Holding Business segment manages affiliated companies within the group. The Other segment is involved in the manufacturing and sale of automotive supplies, as well as the real estate investment.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.61% | 156M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- A096760 Stock
